ST VINCENT'S HOSPITAL MELBOURNE

St Vincent's PET/CT Centre
Basement Level, 41 Victoria Pde, Fitzroy VIC 3065
Tel: 9231 3071 Fax: 9231 3090

Compassion | Justice | Integrity | Excellence

Patient Details: *affix patient label here*		***Handwritten Confirmation of Patient Details***
Surname:	UR:	Name:
First Name:		UR Number:
DOB:		Interpreter Required:
Address:		Language:
Phone:		Is the Patient Diabetic:

Patient Referred From (please specify) Outpatient Clinic/Inpatient Ward:

Requesting Doctor (*please note: Patients MUST be referred by a Specialist to obtain a Medicare Rebate for PET imaging*)

Name:	Phone:	Fax:
Address:	Provider Number:	
	Signature:	Date

Relevant Clinical History

Group 1: Staging/Diagnosis (eligible for Medicare rebate). **Please select the appropriate indication**

Whole Body FDG Study for:

- ☐ Solitary pulmonary nodule (not suitable for FNAB), or if attempt at pathological characterisation has failed
- ☐ Staging of NSCLC (Lung Carcinoma) being considered for curative surgery or radiotherapy
- ☐ Staging of newly diagnosed previously untreated Hodgkin's or non-Hodgkin's lymphoma
- ☐ Staging of biopsy proven newly diagnosed head and neck carcinoma
- ☐ Evaluation of metastatic squamous cell carcinoma from unknown primary involving cervical nodes
- ☐ Staging of newly diagnosed oesophageal carcinoma or GEJ in patients considered suitable for active therapy
- ☐ Further primary staging of histologically proven carcinoma of the uterine cervix (FIGO stage IB2 or greater) prior to planned radical radiotherapy or combined modality therapy with curative intent
- ☐ Initial staging of patients with biopsy proven bone or soft-tissue sarcoma (excluding GIST) considered by conventional staging to be potentially curable
- ☐ Staging of locally advanced (Stage III) Breast cancer

*Please note: the CT performed as part of a PET/CT is for anatomical correlation and is NOT a diagnostic CT. If you require a diagnostic CT, with or without contrast please provide a formal request with clinical information in the space below.

Diagnostic CT region:

Renal Function:
Normal ☐
Abnormal ☐
eGFR:
Date:

PLEASE ENSURE BOTH PAGES OF THE REFERRAL ARE COMPLETED

Tel: 9231 3071 **Fax: 9231 3090**

A/Prof S Schlicht, Dr K Taubman, Dr K Yap, Dr R Shafik-Eid, Dr G Ramaseshan, Dr S Lee

Group 2: Restaging/Recurrence (eligible for a Medicare rebate) **Please select the appropriate indication**

Whole Body FDG Study for:

- ☐ Assess response to first line therapy for Hodgkin's or non-Hodgkin's lymphoma (either during treatment or within 3 months of completing definitive first line treatment
- ☐ Restaging of confirmed recurrence of Hodgkin's or non-Hodgkin's lymphoma
- ☐ Assess response to second line chemotherapy (where stem cell transplantation is being considered) for Hodgkin's or non-Hodgkin's lymphoma
- ☐ Suspected residual or recurrent head and neck carcinoma (after definitive treatment in patients considered suitable for active therapy)
- ☐ Following initial therapy for suspected residual, metastatic or recurrent colorectal carcinoma in patients suitable for active therapy
- ☐ Following initial therapy for suspected metastatic or recurrent malignant melanoma in patients suitable for active therapy
- ☐ Further staging, confirmed recurrence of uterine cervix carcinoma suitable for salvage pelvic chemoradiotherapy or exenteration
- ☐ Suspected residual or recurrent sarcoma (excluding GIST) after initial therapy to assess suitability for subsequent curative treatment
- ☐ Following initial therapy for suspected residual, metastatic or recurrent ovarian carcinoma in patients suitable for active treatment
- ☐ Suspected metastatic, or suspected recurrent Breast cancer

FDG Study of Brain for:

- ☐ Evaluation of refractory epilepsy being evaluated for surgery
- ☐ Suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy or during ongoing chemotherapy, in patients who are considered suitable for active therapy

^{68}Ga-DOTATATE study for:

- ☐ Staging of biochemically suspected GEP Neuroendocrine tumours or assessment of resectability of metastatic GEP neuroendocrine tumours

Group 3: Additional Indications (the following indications are NOT currently eligible for a Medicare rebate*)

- ☐ Brain FDG PET for Neurodegeneration
- ☐ Brain FET-PET for primary or metastatic disease
- ☐ Brain FBB PET for Amyloid for Neurodegeneration
- ☐ Small cell lung carcinoma (note: non-small cell lung funded)
- ☐ Cardiac FDG PET (cardiac sarcoid)
- ☐ Gastric carcinoma (note gastro-esophageal junction funded)
- ☐ Liver or biliary cancer
- ☐ Neuroendocrine carcinoma FDG PET (note ^{68}Ga-DOTA PET funded)
- ☐ Endometrial carcinoma
- ☐ Prostate cancer: ^{18}F-DCPyL (PSR)
- ☐ Myeloma
- ☐ Genetourinary cancers
- ☐ Bone cancers
- ☐ Metastases from unknown primary
- ☐ Infection / Inflammation
- ☐ Other:

*Referrers are asked to ensure patients are aware that there will be a charge for PET scans that do not attract a Medicare rebate.

Clinical Trials

Is the patient on a clinical trial:

If so, what is the trial code:

Who is the trial coordinator: Coordinators signature:

For use by Medical Imaging Staff

Study Protocol Details:

Details of Radiopharmaceutical:

Signature of Medical Specialist: Radiopharmaceutical Label:

SVPR023 03/20

Tel: 9231 3071 **Fax: 9231 3090**

A/Prof S Schlicht, Dr K Taubman, Dr K Yap, Dr R Shafik-Eid, Dr G Ramaseshan, Dr S Lee